2 Green Flags for Ocugen's Future
Shares of Ocugen (NASDAQ: OCGN) skyrocketed last year as the company planned to enter the lucrative coronavirus vaccine market. Unfortunately, the company's candidate, Covaxin, has yet to earn emergency use authorization (EUA) where it matters for Ocugen's purposes.
As a result, shares of the eye disease-focused biotech have crashed, losing 72% of their value in the past three months. While Ocugen looks risky, there are reasons why it has a chance to bounce back.
Let's discuss two green flags for Ocugen's future and decide whether they make shares of this clinical-stage biotech a buy.
Source Fool.com
